MoneyDiscourse
← All companies

BMY

BRISTOL MYERS SQUIBB CO · Health Care

8 quarters · 66 figures · latest Q3 FY2026 filed 2026-10-29 →

Compared

6 of 8 · select any line below to add or remove it ·

  • Total Revenues

    $13.07bn+6.9% Y/Y

    Q3 FY2026

  • Net Earnings/(Loss)

    $2.16bn−1.5% Y/Y

    Q3 FY2026

  • Earnings/(Loss) per Common Share - Diluted

    $1.05−2.8% Y/Y

    Q3 FY2026

  • Gross margin

    68.3%−5.0% Y/Y

    Q3 FY2026

  • Amortization of acquired intangible assets

    $458m−44.9% Y/Y

    Q3 FY2026

  • Cost of products sold

    $4.15bn+20.7% Y/Y

    Q3 FY2026

Reported figures

Click any line for its full history. Each figure links to the filing it was read from.

Income statement

36 lines

LineTrendQ4 FY2025Q1 FY2026Q2 FY2026Q3 FY2026Y/YQ/Q
Amortization of acquired intangible assetsamortization_acquired_intangibles
$826m$437m$437m$458m−44.9%+4.8%
Cost of products soldcost_of_products_sold
$4.1bn$3.42bn$3.73bn$4.15bn+20.7%+11.3%
Earnings/(Loss) per Common Share - Basiceps_basic
$0.53$1.31$1.62$1.06−1.9%−34.6%
Earnings/(Loss) per Common Share - Dilutedeps_diluted
$0.53$1.31$1.62$1.05−2.8%−35.2%
Earnings/(Loss) Per Share - Non-GAAPeps_diluted_non_gaap
$1.26$1.58$2.04$1.35−17.2%−33.8%
Income tax provisionincome_tax_provision
$384m$561m$770m$374m−59.3%−51.4%
Net Earnings/(Loss) Attributable to BMSnet_income_attributable
$1.09bn$2.68bn$3.32bn$2.16bn−1.8%−34.8%
Net earnings/(loss) attributable to BMS used for diluted EPS calculation (Non-GAAP)net_income_attributable_non_gaap
$2.57bn$3.24bn$4.17bn$2.77bn−16.6%−33.7%
Net product salesnet_product_sales
$12.11bn$11.17bn$12.59bn$12.61bn+6.4%+0.1%
Other (income)/expense, netother_income_expense_net
−$51m$32m−$61m$307m+384.3%+603.3%
Earnings/(Loss) Before Income Taxespretax_income
$1.47bn$3.24bn$4.09bn$2.54bn−18.6%−37.9%
Total Expensestotal_expenses
$11.03bn$8.25bn$8.89bn$10.53bn+15.6%+18.5%
Total Revenuestotal_revenue
$12.5bn$11.49bn$12.97bn$13.07bn+6.9%+0.7%
Acquired IPRDacquired_iprd
$1.39bn$94m—$1.56bn+146.1%—
Alliance and other revenuesalliance_and_other_revenues
$391m$321m—$463m+24.5%—
Cost of products sold (Non-GAAP)cost_of_products_sold_non_gaap
—$3.41bn$3.71bn$4.13bn+24.8%+11.4%
Net Earnings/(Loss)net_earnings
$1.09bn—$3.32bn$2.16bn−1.5%−34.8%
Other (income)/expense, net (Non-GAAP)other_income_expense_net_non_gaap
—$173m$126m$93m+145.1%−26.2%
Earnings/(Loss) before income taxes (Non-GAAP)pretax_income_non_gaap
—$3.96bn$4.99bn$3.22bn−24.4%−35.5%
Research and developmentrd_expense
—$2.65bn$2.96bn$2.37bn−6.4%−20.1%
Research and development (Non-GAAP)rd_expense_non_gaap
—$2.24bn$2.32bn$2.36bn−2.8%+2.1%
Selling, general and administrativesga_expense
—$1.62bn$1.83bn$1.7bn−5.0%−7.0%
Selling, general and administrative (Non-GAAP)sga_expense_non_gaap
—$1.62bn$1.83bn$1.7bn−5.0%−7.0%
Acquired IPRD Charges and Licensing Income Net Impact on Earnings/(Loss) Per Shareacquired_iprd_licensing_eps_impact
———−$0.58−190.0%—
Alliance and other revenuesalliance_and_other_revenue
——$385m—+6.9%—
Weighted-Average Common Shares Outstanding: Diluteddiluted_shares
—2,047——+0.3%—
Gross profitgross_profit
$8.41bn———+11.6%—
Gross profit excluding specified itemsgross_profit_non_gaap
$8.99bn———−1.5%—
Income tax provision (Non-GAAP)income_tax_provision_non_gaap
—$723m——+10.9%—
Acquired IPRD Charges and Licensing Income Net Impact on Earnings/(Loss) Per Shareiprd_licensing_eps_impact
—−$0.03——+25.0%—
Acquired IPRD Charges and Licensing Income Net Impact on Earnings/(Loss) Per Shareiprd_licensing_net_eps_impact
−$0.60———−6100.0%—
Net Earnings/(Loss)net_income
—$2.68bn——+8.8%—
Research and developmentresearch_and_development
$2.59bn———−19.0%—
Research and development excluding specified itemsresearch_and_development_non_gaap
$2.56bn———−8.1%—
Selling, general and administrativesga
$2.18bn———+2.1%—
Selling, general and administrative excluding specified itemssga_non_gaap
$2.09bn———−0.9%—

Segments

24 lines

LineTrendQ4 FY2025Q1 FY2026Q2 FY2026Q3 FY2026Y/YQ/Q
Breyanzibreyanzi_revenue
$392m$411m$484m$526m+46.5%+8.7%
Camzyoscamzyos_revenue
$353m$314m$416m$420m+41.9%+1.0%
Cobenfycobenfy_revenue
$51m$56m$63m$57m+32.6%−9.5%
Eliquiseliquis_revenue
$3.45bn$4.14bn$4.48bn$4.69bn+25.2%+4.7%
Total Growth Portfoliogrowth_portfolio_revenue
$7.39bn$6.23bn$7.56bn$7.66bn+11.7%+1.3%
Total Revenues - Int'linternational_revenue
$3.94bn$3.7bn$3.98bn$4bn+2.6%+0.3%
Total Legacy Portfoliolegacy_portfolio_revenue
$5.11bn$5.28bn$5.42bn$5.42bn+0.9%−0.1%
Opdivoopdivo_revenue
$2.69bn$2.15bn$2.49bn$2.37bn−6.2%−4.5%
Opdualagopdualag_revenue
$350m$295m$349m$367m+22.7%+5.2%
Orenciaorencia_revenue
$1.01bn$818m$1.03bn$983m+2.0%−4.9%
Reblozylreblozyl_revenue
$666m$555m$735m$750m+22.0%+2.0%
Revlimidrevlimid_revenue
$602m$349m$425m$303m−47.3%−28.7%
Total Revenues - U.S.us_revenue
$8.56bn$7.79bn$8.99bn$9.07bn+8.9%+0.9%
Yervoyyervoy_revenue
$810m$651m$769m$793m+7.3%+3.1%
Abraxaneabraxane_revenue
—$50m$55m$65m−12.2%+18.2%
Krazatikrazati_revenue
—$50m$55m$58m+9.4%+5.5%
Opdivo Qvantigopdivo_qvantig_revenue
—$163m$261m$334m+398.5%+28.0%
Other Growth Productsother_growth_products_revenue
—$581m$653m$731m+12.3%+11.9%
Other Legacy Productsother_legacy_products_revenue
—$156m$170m$154m−13.0%−9.4%
Pomalyst/Imnovidpomalyst_revenue
$692m$513m$204m—−71.2%−60.2%
Sotyktusotyktu_revenue
—$69m$87m$100m+25.0%+14.9%
Sprycelsprycel_revenue
—$73m$88m$73m−38.7%−17.0%
Zeposiazeposia_revenue
—$118m$169m$168m+4.3%−0.6%
Pomalyst/Imnovidpomalyst_imnovid_revenue
———$130m−80.7%—

Margins

6 lines

LineTrendQ4 FY2025Q1 FY2026Q2 FY2026Q3 FY2026Y/YQ/Q
Effective tax rateeffective_tax_rate
26.2%17.3%18.8%14.8%−49.8%−21.3%
Effective tax rate (Non-GAAP)effective_tax_rate_non_gaap
22.1%18.3%16.5%14.1%−36.8%−14.5%
Gross margingross_margin
67.2%70.2%71.3%68.3%−5.0%−4.2%
Gross margin (Non-GAAP)gross_margin_non_gaap
71.9%70.3%71.4%68.4%−6.2%−4.2%
Operating marginoperating_margin
29.1%———+63.5%—
Operating margin excluding specified itemsoperating_margin_non_gaap
34.8%———+1.5%—

Guided vs delivered

What the company told the market to expect, against what it then reported. Its own guidance is the only benchmark here — no analyst estimates appear anywhere on this site.

Data from company filings. Not investment advice.